OSE Immunotherapeutics SA (OSE.PA)
| Previous Close | 8.98 |
| Open | 9.09 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 9.16 - 9.95 |
| 52 Week Range | 3.12 - 9.95 |
| Volume | |
| Avg. Volume | 205,650 |
| Market Cap | 214.311M |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | 5.68 |
| EPS (TTM) | 1.73 |
| Earnings Date | Sep 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.30 |
GlobeNewswireOSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral presentations selected for international conferences: The Festival of Biologics in Basel, Switzerland (October 17, 2024)The 16th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Barcelona, Spain (November 7, 2024)The Antibody Therapeutics Xchange in Brussels (November 18, 20
- GlobeNewswire
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new partnerships.New strategic partnership with AbbVie for up to $713 million, including $48 million received upon signature.Major partnership expansion with Boehringer Ingelheim: Amendment of the collaboration and licensing agreement on first-in-class SIRPα compounds developed both in immuno-oncology and now expected
